Advances in the management of cancer, particularly the development of new chemotherapeutic agents, have greatly improved the survival and outcome of patients with hematologic malignancies and solid tumors; overall 5-year survival rates in cancer patients have improved from 39% in the 1960s to 60% in the 1990s.1 However, infection, caused by both the underlying malignancy and cancer chemotherapy, particularly myelosuppressive chemotherapy, remains a persistent challenge. © 2006 Springer Science+Business Media, Inc.
CITATION STYLE
Safdar, N., Crnich, C. J., & Maki, D. G. (2006). Infectious complications of cancer therapy. In Oncology: An Evidence-Based Approach (pp. 1372–1409). Springer New York. https://doi.org/10.1007/0-387-31056-8_76
Mendeley helps you to discover research relevant for your work.